-
1
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
-
(2012)
N. Engl. J. Med.
, vol.366
, pp. 2443-2454
-
-
Topalian, S.L.1
-
2
-
-
84862903106
-
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
-
Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012).
-
(2012)
N. Engl. J. Med.
, vol.366
, pp. 2455-2465
-
-
Brahmer, J.R.1
-
3
-
-
84925221855
-
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma
-
Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372, 311-319 (2015).
-
(2015)
N. Engl. J. Med.
, vol.372
, pp. 311-319
-
-
Ansell, S.M.1
-
4
-
-
84923078390
-
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
-
Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558-562 (2014).
-
(2014)
Nature
, vol.515
, pp. 558-562
-
-
Powles, T.1
-
5
-
-
84929481480
-
Pembrolizumab for the treatment of non-small-cell lung cancer
-
Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018-2028 (2015).
-
(2015)
N. Engl. J. Med.
, vol.372
, pp. 2018-2028
-
-
Garon, E.B.1
-
6
-
-
84932628341
-
PD-1 blockade in tumors with mismatch-repair deficiency
-
Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509-2520 (2015).
-
(2015)
N. Engl. J. Med.
, vol.372
, pp. 2509-2520
-
-
Le, D.T.1
-
7
-
-
84946607195
-
Nivolumab versus everolimus in advanced renal-cell carcinoma
-
Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803-1813 (2015).
-
(2015)
N. Engl. J. Med.
, vol.373
, pp. 1803-1813
-
-
Motzer, R.J.1
-
8
-
-
84976511909
-
PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma
-
Nghiem, P. T. et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N. Engl. J. Med. 374, 2542-2552 (2016).
-
(2016)
N. Engl. J. Med.
, vol.374
, pp. 2542-2552
-
-
Nghiem, P.T.1
-
9
-
-
84994812847
-
Nivolumab for recurrent squamous-cell carcinoma of the head and neck
-
Ferris, R. L. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856-1867 (2016).
-
(2016)
N. Engl. J. Med.
, vol.375
, pp. 1856-1867
-
-
Ferris, R.L.1
-
10
-
-
31444451661
-
Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274)
-
Lee, S. J. et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274). FEBS Lett. 580, 755-762 (2006).
-
(2006)
FEBS Lett.
, vol.580
, pp. 755-762
-
-
Lee, S.J.1
-
11
-
-
84973131266
-
Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers
-
Kataoka, K. et al. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature 534, 402-406 (2016).
-
(2016)
Nature
, vol.534
, pp. 402-406
-
-
Kataoka, K.1
-
12
-
-
84960842480
-
MYC regulates the antitumor immune response through CD47 and PD-L1
-
Casey, S. C. et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352, 227-231 (2016).
-
(2016)
Science
, vol.352
, pp. 227-231
-
-
Casey, S.C.1
-
13
-
-
84979502955
-
Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
-
Dorand, R. D. et al. Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity. Science 353, 399-403 (2016).
-
(2016)
Science
, vol.353
, pp. 399-403
-
-
Dorand, R.D.1
-
14
-
-
84984911573
-
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
-
Li, C.-W. et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat. Commun. 7, 12632 (2016).
-
(2016)
Nat. Commun.
, vol.7
, pp. 12632
-
-
Li, C.-W.1
-
15
-
-
85004025764
-
Deubiquitination and stabilization of PD-L1 by CSN5
-
Lim, S. O. et al. Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell 30, 925-939 (2016).
-
(2016)
Cancer Cell
, vol.30
, pp. 925-939
-
-
Lim, S.O.1
-
16
-
-
84920956735
-
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
-
Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567 (2014).
-
(2014)
Nature
, vol.515
, pp. 563-567
-
-
Herbst, R.S.1
-
17
-
-
85008428512
-
What does PD-L1 positive or negative mean?
-
Ribas, A. & Hu-Lieskovan, S. What does PD-L1 positive or negative mean? J. Exp. Med. 213, 2835-2840 (2016).
-
(2016)
J. Exp. Med.
, vol.213
, pp. 2835-2840
-
-
Ribas, A.1
Hu-Lieskovan, S.2
-
18
-
-
70849098603
-
Haploid genetic screens in human cells identify host factors used by pathogens
-
Carette, J. E. et al. Haploid genetic screens in human cells identify host factors used by pathogens. Science 326, 1231-1235 (2009).
-
(2009)
Science
, vol.326
, pp. 1231-1235
-
-
Carette, J.E.1
-
19
-
-
80052851832
-
Ebola virus entry requires the cholesterol transporter Niemann-Pick C1
-
Carette, J. E. et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477, 340-343 (2011).
-
(2011)
Nature
, vol.477
, pp. 340-343
-
-
Carette, J.E.1
-
20
-
-
85020486879
-
Genetic wiring maps of single-cell protein states reveal an off-switch for GPCR signalling
-
Brockmann, M. et al. Genetic wiring maps of single-cell protein states reveal an off-switch for GPCR signalling. Nature 546, 307-311 (2017).
-
(2017)
Nature
, vol.546
, pp. 307-311
-
-
Brockmann, M.1
-
21
-
-
18844457095
-
Mechanisms of type-I- and type-II-interferon-mediated signalling
-
Platanias, L. C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5, 375-386 (2005).
-
(2005)
Nat. Rev. Immunol.
, vol.5
, pp. 375-386
-
-
Platanias, L.C.1
-
22
-
-
12444305419
-
Identification of eight genes encoding chemokine-like factor superfamily members 1-8 (CKLFSF1-8) by in silico cloning and experimental validation
-
Han, W. et al. Identification of eight genes encoding chemokine-like factor superfamily members 1-8 (CKLFSF1-8) by in silico cloning and experimental validation. Genomics 81, 609-617 (2003).
-
(2003)
Genomics
, vol.81
, pp. 609-617
-
-
Han, W.1
-
23
-
-
84930929328
-
Identification of the common origins of osteoclasts, macrophages, and dendritic cells in human hematopoiesis
-
Xiao, Y. et al. Identification of the common origins of osteoclasts, macrophages, and dendritic cells in human hematopoiesis. Stem Cell Rep. 4, 984-994 (2015).
-
(2015)
Stem Cell Rep.
, vol.4
, pp. 984-994
-
-
Xiao, Y.1
-
24
-
-
84882683958
-
The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3
-
Chen, Z. et al. The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3. Immunity 39, 272-285 (2013).
-
(2013)
Immunity
, vol.39
, pp. 272-285
-
-
Chen, Z.1
-
25
-
-
84879703551
-
Strength of PD-1 signaling differentially afects T-cell effector functions
-
Wei, F. et al. Strength of PD-1 signaling differentially afects T-cell effector functions. Proc. Natl Acad. Sci. USA 110, E2480-E2489 (2013).
-
(2013)
Proc. Natl Acad. Sci. USA
, vol.110
, pp. E2480-E2489
-
-
Wei, F.1
-
26
-
-
84857400782
-
Identification of CMTM7 as a transmembrane linker of BLNK and the B-cell receptor
-
Miyazaki, A., Yogosawa, S., Murakami, A. & Kitamura, D. Identification of CMTM7 as a transmembrane linker of BLNK and the B-cell receptor. PLoS ONE 7, e31829 (2012).
-
(2012)
PLoS ONE
, vol.7
, pp. e31829
-
-
Miyazaki, A.1
Yogosawa, S.2
Murakami, A.3
Kitamura, D.4
-
27
-
-
0001677717
-
Controlling the False discovery rate: A practical and powerful approach to multiple testing
-
Benjamini, Y. & Hochberg, Y. Controlling the False discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289-300 (1995).
-
(1995)
J. R. Stat. Soc. B
, vol.57
, pp. 289-300
-
-
Benjamini, Y.1
Hochberg, Y.2
-
28
-
-
84940790892
-
Intra- and inter-tumor heterogeneity in a vemurafenibresistant melanoma patient and derived xenografts
-
Kemper, K. et al. Intra- and inter-tumor heterogeneity in a vemurafenibresistant melanoma patient and derived xenografts. EMBO Mol. Med. 7, 1104-1118 (2015).
-
(2015)
EMBO Mol. Med.
, vol.7
, pp. 1104-1118
-
-
Kemper, K.1
-
29
-
-
84950283765
-
A generic strategy for CRISPR-Cas9-mediated gene tagging
-
Lackner, D. H. et al. A generic strategy for CRISPR-Cas9-mediated gene tagging. Nat. Commun. 6, 10237 (2015).
-
(2015)
Nat. Commun.
, vol.6
, pp. 10237
-
-
Lackner, D.H.1
-
30
-
-
84957605863
-
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
-
Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184-191 (2016).
-
(2016)
Nat. Biotechnol.
, vol.34
, pp. 184-191
-
-
Doench, J.G.1
-
31
-
-
36349004799
-
Selecting highly affine and well-expressed TCRs for gene therapy of melanoma
-
Jorritsma, A. et al. Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood 110, 3564-3572 (2007).
-
(2007)
Blood
, vol.110
, pp. 3564-3572
-
-
Jorritsma, A.1
|